182 related articles for article (PubMed ID: 36528847)
21. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
[TBL] [Abstract][Full Text] [Related]
22. Osteocalcin serum levels in obese patients with type 2 diabetes mellitus: The virtual points observed in a case control study.
Shams HA; Al-Kuraishy HM; Al-Gareeb AI
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S4-S10. PubMed ID: 35130209
[TBL] [Abstract][Full Text] [Related]
23. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients.
Steffensen LB; Feddersen S; Preil SR; Rasmussen LM
Cardiovasc Diabetol; 2018 May; 17(1):72. PubMed ID: 29773082
[TBL] [Abstract][Full Text] [Related]
24. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes.
Rathmann W; Strassburger K; Bongaerts B; Kuss O; Müssig K; Burkart V; Szendroedi J; Kotzka J; Knebel B; Al-Hasani H; Roden M;
Diabetologia; 2019 Feb; 62(2):286-291. PubMed ID: 30413829
[TBL] [Abstract][Full Text] [Related]
25. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
26. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2.
Dong M; Gong ZC; Dai XP; Lei GH; Lu HB; Fan L; Qu J; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):824-9. PubMed ID: 21933224
[TBL] [Abstract][Full Text] [Related]
27. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
Xiao D; Zhang SM; Li X; Yin JY; Gong WJ; Zheng Y; Xu XJ; Lin X; Ji LN; Liu RR; Tang Q; Zhang W; Zhou HH; Han XY; Liu ZQ
Pharmacogenomics; 2015; 16(14):1621-9. PubMed ID: 26401715
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
30. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
Khunti K; Godec TR; Medina J; Garcia-Alvarez L; Hiller J; Gomes MB; Cid-Ruzafa J; Charbonnel B; Fenici P; Hammar N; Hashigami K; Kosiborod M; Nicolucci A; Shestakova MV; Ji L; Pocock S
Diabetes Obes Metab; 2018 Feb; 20(2):389-399. PubMed ID: 28817227
[TBL] [Abstract][Full Text] [Related]
31. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
[TBL] [Abstract][Full Text] [Related]
32. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
33. Metformin inhibits goitrogenous effects of type 2 diabetes.
Ittermann T; Markus MR; Schipf S; Derwahl M; Meisinger C; Völzke H
Eur J Endocrinol; 2013 Jul; 169(1):9-15. PubMed ID: 23572084
[TBL] [Abstract][Full Text] [Related]
34. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Sun W; Zeng C; Liao L; Chen J; Wang Y
Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
[TBL] [Abstract][Full Text] [Related]
35. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
36. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
Li Q; Liu F; Zheng TS; Tang JL; Lu HJ; Jia WP
Acta Pharmacol Sin; 2010 Feb; 31(2):184-90. PubMed ID: 20139901
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
[TBL] [Abstract][Full Text] [Related]
38. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin‑treated Sprague‑Dawley rats with type 2 diabetes mellitus.
Chen Y; Wu Y; Yang Y; Xu Z; Tong J; Li Z; Zhou X; Li C
Int J Mol Med; 2018 Jun; 41(6):3327-3341. PubMed ID: 29512687
[TBL] [Abstract][Full Text] [Related]
40. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
